Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector ® to ...

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. today announced an option to ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

AbbVie is currently addressing serious health ... 30% from Western Europe, Canada, Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil.

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond ...